APA

Boulay A., Zumstein-Mecker S., Stephan C., Beuvink I., Zilbermann F., Haller R., Tobler S., Heusser C., O'Reilly T., Stolz B., Marti A., Thomas G. & Lane H. A. (20040401). Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. : Cancer research.

Chicago

Boulay Anne, Zumstein-Mecker Sabine, Stephan Christine, Beuvink Iwan, Zilbermann Frederic, Haller Roland, Tobler Sonja, Heusser Christoph, O'Reilly Terence, Stolz Barbara, Marti Andreas, Thomas George and Lane Heidi A. 20040401. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. : Cancer research.

Harvard

Boulay A., Zumstein-Mecker S., Stephan C., Beuvink I., Zilbermann F., Haller R., Tobler S., Heusser C., O'Reilly T., Stolz B., Marti A., Thomas G. and Lane H. A. (20040401). Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. : Cancer research.

MLA

Boulay Anne, Zumstein-Mecker Sabine, Stephan Christine, Beuvink Iwan, Zilbermann Frederic, Haller Roland, Tobler Sonja, Heusser Christoph, O'Reilly Terence, Stolz Barbara, Marti Andreas, Thomas George and Lane Heidi A. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. : Cancer research. 20040401.